Karlsson AK, et al. – The efficacy and tolerability of checkpoint inhibitors (ipilimumab, nivolumab, and pembrolizumab) were compared with control interventions (placebo, immunotherapy, or chemotherapy) in patients with stage III or IV unresectable cutaneous melanoma. Outcomes suggested that both in terms of survival and tumor response, checkpoint inhibitors were more effective than control interventions. Moreover, PD1 therapies (nivolumab and pembrolizumab) offered greater efficacy than CTLA4 therapy (ipilimumab). However, the combination of nivolumab and ipilimumab was the most effective, but significantly less tolerable than monotherapy.